Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term Care: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Laboratory Perspectives on Assay Selection and implementation of PlGF-Based Testing for Suspected Preterm Preeclampsia.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
Same author

Comparing Catheters to Fistulas in Older Patients Starting Hemodialysis (ACCESS HD).

Journal of the American Society of Nephrology : JASN·2026
Same author

FLOW Trial - The effect of fluoxetine combined with exercise on motor recovery after stroke: an RCT.

Archives of physical medicine and rehabilitation·2026
Same author

Design and rational of the the PRACTICAL-HERO trial: A randomized trial of higher and lower doses of heparin vs placebo for elective diagnostic coronary angiography.

American heart journal·2026
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

2.8K

The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.

Vladimír Džavík1, Shahar Lavi, Kevin Thorpe

  • 1Interventional Cardiology Program, Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada. vlad.dzavik@uhn.on.ca

Circulation
|November 25, 2010
PubMed
Summary
This summary is machine-generated.

Varespladib, an inhibitor of secretory phospholipase A(2), did not reduce cardiac biomarker release after percutaneous coronary intervention. This study found no significant benefit of sPLA(2) inhibition in preventing myonecrosis in PCI patients.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

2.6K

Related Experiment Videos

Last Updated: May 7, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

2.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

2.6K

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Secretory phospholipase A(2) (sPLA(2)) is implicated in myonecrosis following percutaneous coronary intervention (PCI).
  • Inhibiting sPLA(2) may offer a therapeutic benefit in reducing cardiac damage post-PCI.
  • Varespladib is a small-molecule inhibitor targeting sPLA(2).

Purpose of the Study:

  • To investigate the efficacy of varespladib in reducing postprocedural cardiac biomarker release after elective PCI.
  • To test the hypothesis that sPLA(2) inhibition with varespladib mitigates myonecrosis associated with PCI.

Main Methods:

  • A phase II, randomized, placebo-controlled trial involving 144 stable patients undergoing elective PCI.
  • Patients received either varespladib (500 mg PO BID) or placebo for 3-5 days before and 5 days after the procedure.
  • Primary endpoint: elevation of troponin I or creatine kinase-MB above the upper limit of normal at 6-8 or 18-24 hours post-PCI.

Main Results:

  • The primary endpoint occurred in 75% of varespladib patients versus 63% of placebo patients (P=0.14), indicating no significant reduction.
  • Elevated troponin I (3x ULN) was observed in 57% vs. 50% (P=0.39), and elevated CK-MB (2x ULN) in 14% vs. 3% (P=0.018).
  • Varespladib significantly reduced sPLA(2) activity, but did not impact high-sensitivity C-reactive protein levels.

Conclusions:

  • Administration of varespladib for 3-5 days prior to elective PCI did not reduce periprocedural myonecrosis.
  • Inhibition of sPLA(2) with varespladib did not demonstrate a significant benefit in this patient population.
  • Further research may be needed to explore other therapeutic strategies for preventing PCI-related myonecrosis.